Clinical Trial Details

Inclusion Criteria:

• Child 1 month to < 18 years

• Child newly diagnosed, i.e., within 16 weeks (112 days) from time of diagnosis of cancer not including the day of diagnosis, OR

• Child with relapsed cancer, defined as within 16 weeks (112 days) of first-time relapse/evidence of progression of disease as noted by scan or biopsy after previous diagnosis of cancer.

• Child provide assent if age ≥ 7 years

• Poor prognosis, i.e., approximate < 25 % estimated overall survival or at the discretion of the attending AND/OR:

• Falls into one of the following diagnosis categories, including but not limited to:

  • Atypical teratoid rhabdoid tumor
  • Glioblastoma multiforme
  • Diffuse intrinsic brainstem glioma
  • Embryonal tumors with multilayered rosettes
  • Other high-grade glioma
  • Gliomatosis cerebri
  • Metastatic osteosarcoma
  • Metastatic Ewing sarcoma
  • Metastatic rhabdomyosarcoma
  • Metastatic desmoplastic small round cell tumor (DSRCT)
  • Other metastatic sarcoma/carcinoma-at discretion of attending
  • Metastatic unknown primary- or rare pathology- at discretion of attending

• Parent(s) legal decision-maker(s) for child

• Parent(s) ≥18 years of age

• Parent (s) Informed of child's cancer diagnosis

• Parent(s) Able to read, speak and understand English

• Must be willing to be audio recorded during all study sessions.

Exclusion Criteria:

• The parent has neurological/cognitive impairments likely to interfere with study participation;
• The child ≥ 7 years of age does not provide assent
• Parent refuses to be audio recorded during sessions.